SARS-CoV-2 感染中的免疫反应：I 型和 III 型干扰素的作用。
Immune response in SARS-CoV-2 infection: the role of interferons type I and type III.
机构信息
Universidade Federal do Piauí, Centro de Ciências da Saúde, Departamento de Parasitologia e Microbiologia, Teresina, PI, Brazil.
Universidade Federal da Bahia, Faculdade de Medicina, Laboratório de Pesquisa em Infectologia (LAPI), Salvador, BA, Brazil.
出版信息
Braz J Infect Dis. 2020 Sep-Oct;24(5):428-433. doi: 10.1016/j.bjid.2020.07.011. Epub 2020 Aug 26.
Abstract
BACKGROUND
There is scarce information on the human immune response to the SARS-CoV-2 infection, and on the exacerbated inflammatory reaction observed in severe COVID-19 cases.
OBJECTIVE
To review the available evidence on the role of interferons type I and type III to SARS-CoV-2 infection.
METHODS
We reviewed the available published evidence on the role of immune response to SARS-CoV-2 infection as well as recent publications on characteristics and outcomes of COVID-19, and their relationship with interferons type I and type III.
RESULTS
The available data indicates that immune response plays an important role in controlling SARS-CoV-2 infection and the immune dysregulation can significantly modify the clinical outcomes of affected patients. In addition, the evidence suggests that IFN type I and III can play an important role in controlling viremia and modulating the immune response in COVID-19.
CONCLUSIONS
Due to their central role in immune response against SARS-CoV-2 infection, IFN type I and III could be considered for treatment of COVID-19.
摘要
背景
目前关于人类对 SARS-CoV-2 感染的免疫反应，以及在严重 COVID-19 病例中观察到的炎症反应加剧的信息有限。
目的
综述 I 型和 III 型干扰素在 SARS-CoV-2 感染中的作用的现有证据。
方法
我们综述了有关 SARS-CoV-2 感染免疫反应的现有已发表证据，以及关于 COVID-19 的特征和结局及其与 I 型和 III 型干扰素的关系的最新出版物。
结果
现有数据表明，免疫反应在控制 SARS-CoV-2 感染方面起着重要作用，免疫失调可显著改变受影响患者的临床结局。此外，有证据表明，IFN 型 I 和 III 可在控制病毒血症和调节 COVID-19 中的免疫反应方面发挥重要作用。
结论
由于它们在针对 SARS-CoV-2 感染的免疫反应中的核心作用，I 型和 III 型干扰素可考虑用于 COVID-19 的治疗。
相似文献
1
Immune response in SARS-CoV-2 infection: the role of interferons type I and type III.SARS-CoV-2 感染中的免疫反应：I 型和 III 型干扰素的作用。
Braz J Infect Dis. 2020 Sep-Oct;24(5):428-433. doi: 10.1016/j.bjid.2020.07.011. Epub 2020 Aug 26.
2
A role for retinoids in the treatment of COVID-19?视黄醇类药物在治疗 COVID-19 中的作用？
Clin Exp Pharmacol Physiol. 2020 Oct;47(10):1765-1767. doi: 10.1111/1440-1681.13354. Epub 2020 Jun 11.
3
Type 1 interferons as a potential treatment against COVID-19.1 型干扰素作为一种对抗 COVID-19 的潜在治疗方法。
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
4
Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response.SARS-CoV-2 感染的支气管上皮细胞中的蛋白编码和长非编码 RNA（lncRNA）转录组阐明了干扰素和炎症反应的作用。
Genes (Basel). 2020 Jul 7;11(7):760. doi: 10.3390/genes11070760.
5
SARS-CoV-2 viremia may predict rapid deterioration of COVID-19 patients.SARS-CoV-2 病毒血症可能预示着 COVID-19 患者病情迅速恶化。
Braz J Infect Dis. 2020 Nov-Dec;24(6):565-569. doi: 10.1016/j.bjid.2020.08.010. Epub 2020 Sep 15.
6
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在妊娠晚期感染：来自中国武汉的 18 例患者报告。
BMC Pregnancy Childbirth. 2020 Jul 8;20(1):394. doi: 10.1186/s12884-020-03026-3.
7
Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells.转录组分析揭示了 SARS-CoV-2 感染人肺细胞的新机制。
Immun Inflamm Dis. 2020 Dec;8(4):753-762. doi: 10.1002/iid3.366. Epub 2020 Oct 30.
8
COVID-19: a conundrum to decipher.COVID-19：一个待破译的谜。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.
9
Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review.新型冠状病毒肺炎的潜在抑制剂和功能性食品成分作为 COVID-19 的营养补充剂：综述。
Plant Foods Hum Nutr. 2020 Dec;75(4):458-466. doi: 10.1007/s11130-020-00861-9. Epub 2020 Oct 10.
10
Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?大麻素受体 2：在严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2，即 CoV-19）感染中是否为一个可能的靶点？
Int J Mol Sci. 2020 May 27;21(11):3809. doi: 10.3390/ijms21113809.
引用本文的文献
1
STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy.STING 激动剂作为有前途的疫苗佐剂，可增强针对 SARS 相关冠状病毒感染的免疫原性：自噬的可能作用。
Cell Commun Signal. 2024 Jun 3;22(1):305. doi: 10.1186/s12964-024-01680-0.
2
SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks".SARS-CoV-2 与先天免疫：好、坏与“恰到好处”。
Cell Mol Immunol. 2024 Feb;21(2):171-183. doi: 10.1038/s41423-023-01104-y. Epub 2023 Nov 20.
3
Systematic levels of IL-29 and microRNA185-5p were not associated with severe COVID-19 in the Iranian population.伊朗人群中白细胞介素-29 和 microRNA185-5p 的系统水平与严重 COVID-19 无关。
Virol J. 2023 May 5;20(1):88. doi: 10.1186/s12985-023-02046-7.
4
An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19.基于纳米颗粒的策略对抗病毒感染的概述，重点关注 COVID-19。
J Nanobiotechnology. 2022 Oct 8;20(1):440. doi: 10.1186/s12951-022-01625-0.
5
Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.有潜力的抗 SARS-CoV-2 天然产物：结构、功能和临床试验。
Phytother Res. 2022 Oct;36(10):3833-3858. doi: 10.1002/ptr.7580. Epub 2022 Aug 5.
6
A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19).关于冠状病毒病 (COVID-19) 期间免疫反应和衰竭的综合综述。
Cell Commun Signal. 2022 Jun 2;20(1):79. doi: 10.1186/s12964-022-00856-w.
7
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.初次感染 SARS-CoV-2 后，免疫功能障碍持续 8 个月。
Nat Immunol. 2022 Feb;23(2):210-216. doi: 10.1038/s41590-021-01113-x. Epub 2022 Jan 13.
8
Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract.呼吸道合胞病毒和流感病毒的连续感染可调节 SARS-CoV-2 在呼吸道的复制能力。
Emerg Microbes Infect. 2022 Dec;11(1):412-423. doi: 10.1080/22221751.2021.2021806.
9
Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients.年龄对住院COVID-19患者固有免疫和适应性免疫的影响。
J Clin Med. 2021 Oct 19;10(20):4798. doi: 10.3390/jcm10204798.
10
Mutational Landscape and Interaction of SARS-CoV-2 with Host Cellular Components.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的突变图谱及其与宿主细胞成分的相互作用
Microorganisms. 2021 Aug 24;9(9):1794. doi: 10.3390/microorganisms9091794.
本文引用的文献
1
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
2
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.COVID-19 患者的病理性炎症：单核细胞和巨噬细胞的关键作用。
Nat Rev Immunol. 2020 Jun;20(6):355-362. doi: 10.1038/s41577-020-0331-4. Epub 2020 May 6.
3
Racial Capitalism: A Fundamental Cause of Novel Coronavirus (COVID-19) Pandemic Inequities in the United States.种族资本主义：美国新冠病毒大流行不平等现象的根本原因。
Health Educ Behav. 2020 Aug;47(4):504-508. doi: 10.1177/1090198120922942. Epub 2020 Apr 26.
4
COVID-19 exacerbating inequalities in the US.新冠疫情加剧美国的不平等现象。
Lancet. 2020 Apr 18;395(10232):1243-1244. doi: 10.1016/S0140-6736(20)30893-X.
5
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.SARS-CoV-2 和 SARS-CoV 在人肺中的比较复制和免疫激活特征：一项具有 COVID-19 发病机制意义的离体研究。
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409. doi: 10.1093/cid/ciaa410.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
8
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
9
Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern.编辑按语：世界卫生组织宣布新型冠状病毒（2019-nCoV）为国际关注的第六次突发公共卫生事件。
Euro Surveill. 2020 Feb;25(5). doi: 10.2807/1560-7917.ES.2020.25.5.200131e. Epub 2020 Jan 31.
10
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
Zotero 插件